AC Immune Reports First Quarter 2018 Financial Results and Corporate Update

• Announced first-in-human study for an alpha-synuclein PET tracer for Parkinson's disease
• Selected Tau small molecules (Tau Morphomers) have entered into IND/CTA^* enabling studies; Phase 1 to commence by the end of 2018
• Increased R&D investment and resources across our key programs
• Financial position remains strong with CHF 109.7 million in cash, allowing the Company to be fully financed through Q2 2019, excluding potential incoming milestones

Find the full media release below.